Merck Sharp & Dohme Corp. v. Aurobindo Pharma, Ltd. et al
| Merck Sharp & Dohme Corp. |
| Aurobindo Pharma, Ltd. and Aurobindo Pharma USA Inc. |
| 1:2020cv01099 |
| August 21, 2020 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on October 9, 2020. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 22 NOTICE OF SERVICE of Plaintiff Merck Sharp & Dohme Corp.s Third Supplemental Responses and Objections to Defendants First Set of Joint Interrogatories (Nos. 1-10) filed by Merck Sharp & Dohme Corp..(Silver, Daniel) |
| Filing 21 NOTICE OF SERVICE of Initial Infringement Contentions of Plaintiff Merck Sharp & Dohme Corp. filed by Merck Sharp & Dohme Corp..(Silver, Daniel) |
| Filing 20 MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore and James E. Nealon - filed by Aurobindo Pharma USA Inc., Aurobindo Pharma, Ltd., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Ormerod, Eve) |
SO ORDERED, re (21 in 20-cv-949-RGA; 20 in 20-cv-1099-RGA; 246 in 19-md-2902-RGA) MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore and James E. Nealon, filed by Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited, Aurobindo Pharma, Ltd., Aurobindo Pharma USA Inc.. Signed by Judge Richard G. Andrews on 10/8/2020. Associated Cases: 1:19-md-02902-RGA, 1:20-cv-00949-RGA, 1:20-cv-01099-RGA(nms)
|
| Filing 19 Amended NOTICE of Deposition of Nurit Perlman by Merck Sharp & Dohme Corp. (Silver, Daniel) |
| Filing 18 NOTICE OF SERVICE of Plaintiff Merck Sharp & Dohme Corp.'s Responses and Objections to Defendants' Second Set of Joint Interrogatories (Nos. 11-13) filed by Merck Sharp & Dohme Corp..(Joyce, Alexandra) |
| Filing 17 NOTICE OF SERVICE of 1) produced their Core Technical Documents Pursuant to Paragraph 4(b) of the Default Standard, 2) produced the DMF for the Sitagliptin API used in its ANDA Product pursuant to Paragraph 3(c)(ii) of the Scheduling Order, and 3) disclosed to Plaintiff whether Aurobindo could produce reasonable quantities of unexpired samples of Aurobindos ANDA Products and API. filed by Aurobindo Pharma USA Inc., Aurobindo Pharma, Ltd., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Ormerod, Eve) |
| Pro Hac Vice Attorney Alexander S. Zolan for Merck Sharp & Dohme Corp. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-cv-00749-RGA et al.(kmd) |
| Filing 16 ANSWER to #8 Answer to Complaint, Counterclaim by Merck Sharp & Dohme Corp..(Silver, Daniel) |
| Filing 15 ORAL ORDER: This matter has been referred to Chief Magistrate Judge Mary Pat Thynge for ADR. Counsel are to advise on or before 10/20/20 by a JOINT EMAIL to Judge Thynge, with a copy to her Judicial Administrator, Ms. Kennedy, their clients interest in mediation and the timing when mediation is preferred with a very brief explanation why. When referencing the timing for mediation, counsel rely on certain events in the scheduling order, for example, before claim construction briefing, after the close of discovery, before expert reports and the like, they are to include the date(s) on when such event(s) occur. Ordered by Chief Magistrate Judge Mary Pat Thynge on 9/29/20. Associated Cases: 1:20-cv-00949-RGA, 1:20-cv-01099-RGA(cak) |
| CASE REFERRED to Chief Magistrate Judge Mary Pat Thynge for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at # https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf Associated Cases: 1:20-cv-00949-RGA, 1:20-cv-01099-RGA(cak) |
| Pro Hac Vice Attorney Bruce R. Genderson for Merck Sharp & Dohme Corp. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 20-cv-1227-RGA; 20-cv-1099-RGA; 20-cv-776-RGA; 20-cv-815-RGA; 20-cv-749-RGA; 20-cv-847-RGA; 20-cv-949-RGA (myr) |
| Filing 14 NOTICE OF SERVICE of 1) Default Standard Paragraph 3 Initial Disclosures and 2) Rule 26 Initial Disclosures filed by Aurobindo Pharma USA Inc., Aurobindo Pharma, Ltd., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Ormerod, Eve) |
| Filing 13 NOTICE OF SERVICE of (1) Plaintiffs Initial Disclosures Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure and Paragraph 3 of the Delaware Default Standard for Discovery; and (2) Plaintiffs Initial Disclosures Identifying Defendants Accused Products and Plaintiffs Asserted Patents filed by Merck Sharp & Dohme Corp..(Silver, Daniel) |
|
Filing 12
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 1/22/2021. Amended Pleadings due by 1/22/2021. Fact Discovery completed by 1/22/2021. A Pretrial Conference is set for 9/10/2021, at 9:00 AM in Courtroom 6A. A 3 day Bench Trial is set to start 10/4/2021, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 9/28/2020. Associated Cases: 1:19-md-02902-RGA, 1:20-cv-00949-RGA, 1:20-cv-01099-RGA(nms)
|
| Filing 11 MOTION for Pro Hac Vice Appearance of Attorney Bruce R. Genderson, Jessamyn S. Berniker, Stanley E. Fisher, Alexander S. Zolan, Elise Baumgarten, Shaun P. Mahaffy, Anthony H. Sheh, and Jingyuan Luo - filed by Merck Sharp & Dohme Corp.. (Attachments: #1 Certifications for Bruce R. Genderson, Jessamyn S. Berniker, Stanley E. Fisher, Alexander S. Zolan, Elise Baumgarten, Shaun P. Mahaffy, Anthony H. Sheh, and Jingyuan Luo)(Silver, Daniel) |
| Pro Hac Vice Attorney Jingyuan Luo for Merck Sharp & Dohme Corp. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-cv-00749-RGA et al.(kmd) |
| Pro Hac Vice Attorney Anthony H. Sheh for Merck Sharp & Dohme Corp. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-cv-00749-RGA et al.(kmd) |
|
SO ORDERED, re (9 in 20-cv-1227-RGA; 11 in 20-cv-1099-RGA; 30 in 20-cv-776-RGA; 19 in 20-cv-815-RGA; 21 in 20-cv-749-RGA; 19 in 20-cv-847-RGA; 12 in 20-cv-949-RGA)MOTION for Pro Hac Vice Appearance of Attorney Bruce R. Genderson, Jessamyn S. Berniker, Stanley E. Fisher, Alexander S. Zolan, Elise Baumgarten, Shaun P. Mahaffy, Anthony H. Sheh, and Jingyuan Luo, filed by Merck Sharp & Dohme Corp.. Signed by Judge Richard G. Andrews on 9/28/2020. Associated Cases: 1:20-cv-00749-RGA et al.(nms)
|
| Filing 10 PROPOSED Scheduling Order, by Merck Sharp & Dohme Corp.. (Silver, Daniel) Modified on 9/28/2020 (nms). |
| Filing 9 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Ltd. for Aurobindo Pharma USA Inc. filed by Aurobindo Pharma USA Inc., Aurobindo Pharma, Ltd.. (Belgam, Neal) |
| Filing 8 ANSWER to #1 Complaint, and Additional Defenses and COUNTERCLAIMS against Merck Sharp & Dohme Corp., by Aurobindo Pharma USA Inc., Aurobindo Pharma, Ltd..(Ormerod, Eve) Modified on 9/16/2020 (nms). |
| Filing 7 STIPULATION TO EXTEND TIME to Answer, Move, or Otherwise Respond to Complaint to September 28, 2020 - filed by Aurobindo Pharma USA Inc., Aurobindo Pharma, Ltd.. (Ormerod, Eve) |
|
SO ORDERED, re #7 STIPULATION TO EXTEND TIME to Answer, Move, or Otherwise Respond to Complaint to September 28, 2020 (*Reset Answer Deadlines: Aurobindo Pharma USA Inc. answer due 9/28/2020; Aurobindo Pharma, Ltd. answer due 9/28/2020). Signed by Judge Richard G. Andrews on 8/27/2020. (nms)
|
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Filing 6 DECLARATION of Service, by Merck Sharp & Dohme Corp.. (Joyce, Alexandra) Modified on 8/26/2020 (nms). |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Merck & Co., Inc. for Merck Sharp & Dohme Corp. filed by Merck Sharp & Dohme Corp.. (mal) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,326,708. (mal) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than 7/10/2020. Date of Expiration of Patent: 11/24/2026.Thirty Month Stay Deadline: No earlier than 1/10/2023. (mal) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Filing 1 COMPLAINT filed with Jury Demand against Aurobindo Pharma USA Inc., Aurobindo Pharma, Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number ADEDC-3145522.) - filed by Merck Sharp & Dohme Corp.. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(mal) |
| No Summons Issued. (mal) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
